OUR TEAM
WHAT WE DO
PUBLICATIONS

Board of Directors

Patrick James
Chariman
Former Chairman and CEO
of Micronutrients at The Heritage Group
Connect
Aaron Schacht
CEO, BiomEdit
Connect
Barbara Bodem
Former CFO, Dentsply
Sirona and Hillrom
Connect
Paul Casady
Brakke Consulting, Former Executive at Merial (Boehringer Ingelheim) and Intervet/Schering-Plough (Merck)
Connect
Brett Wong
Principal, Anterra Capital
Connect

Microbiome innovation for animal health.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Our investors and supporters

Microbiome Innovation for Animal Health

LinkedIn
© 2023 · All rights reserved
Legal

Microbiome innovation for animal health.

BiomEdit is an innovation company that discovers, designs, and develops novel probiotics, microbiome derived bioactives, and engineered microbial medicines to address unmet needs in animal health.

Board of Directors

Meet the BiomEdit team

The BiomEdit team is a diverse and balanced mix of both experienced executives and new talent. This includes 20 PhD scientists occupying positions in Discovery, Development, Analytics, Regulatory, and Marketing. Collectively, the team has over 200 peer-reviewed publications and almost 50 patents, and 30% of us have experience taking a new product to market.

Patrick James
Chariman
Former Chairman and CEO of Micronutrients at The Heritage Group
Connect
Aaron Schacht
CEO, BiomEdit
Connect
Barbara Bodem
Former CFO, Dentsply Sirona and Hillrom
Connect
Paul Casady
Brakke Consulting, Former Executive at Merial (Boehringer Ingelheim) and Intervet/Schering-Plough (Merck)
Connect
Brett Wong
Principal, Anterra Capital
Connect
Our investors and supporters

Microbiome innovation for
animal health

LinkedIn
© 2023 · All rights reserved
Legal

Board of Directors

Patrick James
Chariman
Former Chairman and CEO of Micronutrients at The Heritage Group
Connect
Aaron Schacht
CEO, BiomEdit
Connect
Barbara Bodem
Former CFO, Dentsply Sirona and Hillrom
Connect
Paul Casady
Brakke Consulting, Former Executive at Merial (Boehringer Ingelheim) and Intervet/Schering-Plough (Merck)
Connect
Brett Wong
Principal, Anterra Capital
Connect
Our platform is based on samples of microbial populations collected from a large number of animals.

These samples represent what the microbiome looks like in healthy, diseased, and dysbiotic states. These populations are then characterized at the genomic, transcriptomic, and metabolomic levels to generate a microbial atlas for each animal species: a comprehensive dataset describing what bacteria are present, how abundant they are, and what functions they perform within that ecosystem.

Microbial atlases provide us with a wealth of resources to draw from and allow us to identify novel candidate probiotic species with unique functions and properties. Rather than being limited to the chance discovery of a bacterial strain with beneficial effects, we are able to selectively identify strains with desired characteristics. We also use a similar approach to the discovery of bioactive microbial metabolites and peptides. In some applications, new probiotic species are then engineered to produce proteins that can direct the immune response, similarly to a vaccine or an anti-toxin.

Our discovery platform generates three different types of products: probiotics, bioactive compounds, and engineered microbial medicines.

Our investors and supporters

Microbiome innovation for
animal health

LinkedIn
Press
Board of directors
contact us